For the better part of 30 years, irony pursued Charles A. LeMaistre, M.D., from one career move to another.
A committed scientist, teacher, and physician, LeMaistre initially wanted nothing to do with administration. But administration wanted him and the leadership qualities he demonstrated at an early age.
The irrepressible force eventually overcame the immovable object.
At the end of August, LeMaistre will retire, concluding a distinguished medical career after 18 years as president of the University of Texas M. D. Anderson Cancer Center in Houston. Looking back on that career, LeMaistre sees his early aversion to administrative responsibilities in a different light today.
"There is no doubt in my mind that everything I did before [M. D. Anderson] was preparation, so that I could come to this institution and be a part of it," he said.
An Interest in TB
The preparation began in 1947, with graduation from Cornell University Medical College, New York. He completed internship and residency at New York Hospital, and in 1951 returned to Cornell as a Public Health Service postdoctoral research fellow in infectious diseases. ("I still don't consider myself an oncologist," he said.) Early on, he developed an interest in tuberculosis.
"My interest in tuberculosis came about as a result of an opportunity to work with one of the great teachers at Cornell, Dr. Carl Muschenheim, who was one of the world's leading authorities on tuberculosis," said LeMaistre. "It was an exciting time because we were on the verge of finding a therapy that would cure tuberculosis, or at least contain the disease."
In 1954, at the age of 29, LeMaistre was offered a department chairmanship at Cornell.
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Rather than accept the offer, he left "a place I thought I would never want to leave. I really didn't want to become an administrator. I was having too much fun -seeing patients, teaching in many different levels of medicine, and conducting research."
LeMaistre moved on to Emory University, where he continued his work in infectious diseases and developed a particular interest in prevention. He even helped set up a department of preventive medicine and served as its first chairman. But eventually he left Emory (in 1959) because of his desire to devote his full attention to teaching, research, and patient care.
The call of administration followed LeMaistre to the University of Texas Southwestern Medical Center in Dallas. He relented in 1965, when he accepted the title of associate dean, but continued his research, teaching, and patient care activities.
Outspoken Opponent
While in Dallas, LeMaistre accepted another appointment that eventually would make him a major voice in cancer prevention and an outspoken opponent of smoking and tobacco use. As a member of the 1964 Surgeon General's Advisory Committee on Smoking and Health, he helped draft the first public advisory on the health hazards of cigarettes.
The experience with the committee remains a high point in LeMaistre's evaluation of his career.
"It was an unexpected opportunity for a number of people who were not known authorities in the controversy to render an opinion based on existing evidence," he said. For [the report] to have turned out as well as it did was most satisfying, and I feel it has played a very important part in gaining an understanding of the significance of tobacco in illness and disease. I have tremendous admiration for the other members of the committee and for [then Surgeon General] Luther Terry."
News. News
The report remains a remarkable exercise in scientific inquiry for three major reasons: 1) none of the committee members was a critic of tobacco use at the time; 2) a majority of the committee members were tobacco users (LeMaistre was a pipe smoker); and 3) representatives of the tobacco industry participated in the screening of prospective committee members.
"I guess you could say that the committee was heavily weighted in terms of personal bias toward tobacco use," said LeMaistre, "But about halfway through the process, we began to see some change in individual members' opinions and in their desire to stop smoking, long before the conclusions were drawn or the report was written." (LeMaistre himself gave up his pipe smoking.)
'To see each of the succeeding Surgeon General's reports build on the original report and to see all the research that has been conducted has been very rewarding to those of us who were on that first committee."
In 1966, LeMaistre accepted what he thought would be a 3-month assignment at the University of Texas System in Austin. Ninety days turned into 12 years of service, first as vice chancellor for health affairs and then as chancellor of the multicampus university system. The Austin stay ended in 1978 when LeMaistre went to Houston to be president of M. D. Anderson.
World Leader world leader in outpatient care for cancer patients. Anderson has the nation's largest ambulatory treatment and ambulatory surgery programs in cancers. LeMaistre has encouraged development of chemoprevention programs for a variety of cancers. Gene therapy has moved forward on a number of fronts at Anderson, where investigators have participated in the initial trials of genetic approaches to ovarian, breast, and lung cancers.
In 1991, LeMaistre was instrumental in winning approval for the largest building program in the cancer center's history. He also was actively involved in a $151 million capital campaign that provided much of the funding for three additional structures, the first of which will open this year.
LeMaistre has made fiscal stability a priority in the era of managed care, increasing competition, and financial pressures. The center adopted a strategic agenda to preserve research-based patient care. In 1998, almost 85% of Anderson's income will come from patient care fees, external sources of research funding, and private philanthropy.
Despite the recognition and stature of his institution, LeMaistre prefers to work quietly, avoiding the limelight. He is loath to take credit for institutional accomplishments.
" 
A Multitalented Man
John Seffrin, Ph.D., chief executive officer for the American Cancer Society, called LeMaistre "one of the giants in the cancer control field, in no small measure because he is a unique, multitalented man. Mickey LeMaistre is an admixture of political savvy, scientific orientation, and sophistication. He is a consummate administrator who also has the passion necessary to make substantive change. I cannot think of another contemporary leader in cancer control who has made a bigger contribution on behalf of people facing cancer." Some time after August 31, LeMaistre and his wife of 44 years plan to move to their lake home in Austin. He has no specific retirement plans aside from the desire "to spend more time with my wife to make up for all the time that we have not had together in the past." He also expects to have more
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News. News time to spend with his four children and six grandchildren. LeMaistre departs M. D. Anderson at what he considers "the most exciting time in the history of cancer. We are on the verge of pushing so many fundamental basic science discoveries to the bedside that will either improve cancer therapy or prevent cancer. All the fundamental tools are emerging to do this."
In particular, he cites developments in the identification of molecular markers for cancer, which ultimately may lead to more effective therapies and to new approaches to prevention.
Though he leaves open the possibility of continued involvement in cancer control, LeMaistre clearly envisions a low-profile role in the future.
"I'll be involved to the extent that I can be of help," he said. "I'm not actually a crusader. I have great confidence that an informed public will make the right decisions. I might remain involved in education and in trying to get the facts, as they really are, to the public."
If he could write his own epitaph, LeMaistre would offer a simple assessment of his life. "I've been blessed. That's all," he said. "When you have the opportunities that I've had, that's far more than anyone has a right to expect. Every one of them has been different, and each one has been enjoyable."
To his successor, John Mendelsohn, M.D., former chairman of medicine at Memorial Sloan-Kettering Cancer Center in New York, LeMaistre has only a few simple insights to offer.
"Remember that the accomplishments of this institution have always been a team effort. To be part of a team is essential. Be a leader, if that is appropriate," said LeMaistre.
-Charles Bankhead
Is Chemoprevention Overrated or Underfunded?
Researchers in the field of diet and cancer seem to repeatedly prove the adage, "an ounce of prevention is worth a pound of cure." Diet studies spanning the last 15 years presented at the most recent American Association for Cancer Research meeting in Washington, D.C., led to the same conclusion as an earlier landmark report: one-third of all cancer deaths are avoidable by changes in diet.
But trying to isolate the exact substances in food that are beneficial is not easy -as shown by the mixed results of chemoprevention trials. Some investigators believe that the best way to proceed is food supplementation trialsgiving people kale and carrots, rather than beta carotene pills. But others question whether chemoprevention trials are worth the time and money, because the lack of intermediate biomarkers that predict cancer has made them long and costly.
Dramatic Shift
The association between diet and cancer deaths is well established. There has been a dramatic shift in the focus of cancer prevention in recent years, however, from an emphasis on the adverse effects of fat and other dietary components, to the importance of the positive effects of fruits and vegetables.
'The most compelling evidence of the last decade has indicated the importance of protective factors, largely unidentified, in fruits and vegetables," Both reports list avoidable deaths by organ site and calculated identical percentages for all sites, with the exception of colon and prostate. Willett estimated that 70% of colon cancer deaths are linked to diet, compared with Doll and Peto's estimate of 90%, because of clear evidence since 1981 that physical activity plays an important protective role in colon cancer. (Red meat and animal fat appear to be the dietary culprits most strongly associated with colon cancer).
As for the prostate discrepancy, in 1981 there was not enough evidence to link diet and prostate cancer, so Doll
